The NICHE-2 trial demonstrated the efficacy of Nivolumab + Ipilimumab therapy for resectable dMMR colon cancer [66], and the NICHE-3 trial reported the efficacy of Nivolumab + relatlimab, an anti-LAG-3 antibody, for resectable dMMR colon cancer [67]. The gene discussed is LAG3; the disease is malignant colon neoplasm.